Compare HON & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HON | VRTX |
|---|---|---|
| Founded | 1885 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.4B | 115.7B |
| IPO Year | 2012 | 2006 |
| Metric | HON | VRTX |
|---|---|---|
| Price | $230.48 | $456.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 29 |
| Target Price | $249.92 | ★ $539.69 |
| AVG Volume (30 Days) | ★ 4.8M | 1.1M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | 1.29 | ★ 4.02 |
| Revenue | ★ $36,529,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $6.74 | $10.79 |
| Revenue Next Year | $5.91 | $10.47 |
| P/E Ratio | $177.24 | ★ $113.63 |
| Revenue Growth | 12.92 | ★ 46.20 |
| 52 Week Low | $186.76 | $362.50 |
| 52 Week High | $248.18 | $509.98 |
| Indicator | HON | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 58.55 |
| Support Level | $220.64 | $452.54 |
| Resistance Level | $242.65 | $464.15 |
| Average True Range (ATR) | 7.34 | 10.82 |
| MACD | 0.85 | 1.96 |
| Stochastic Oscillator | 68.08 | 77.60 |
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies, industrial automation, energy and sustainability solutions, and building automation. Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around one third of its revenue from recurring aftermarket services.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.